{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"158"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"}],"units":"Participants"}],"description":"Number of subjects with samples available for duvelisib Pharmacokinetics (PK)","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"}],"paramType":"NUMBER","populationDescription":"Intent to Treat for duvelisib patients, no PK samples were collected for ofatumumab patients.","reportingStatus":"POSTED","timeFrame":"Cycle 2, Cycle 3, and Cycle 7","title":"Number of Subjects With Samples Available for Duvelisib Pharmacokinetics (PK)","type":"SECONDARY","unitOfMeasure":"participants"}